Research location
Merewether
New South Wales, Australia
Advertisement
Research activity in Merewether
New South Wales, AustraliaCureCurrent currently publishes aggregate city-level research activity for this location: 32 trials and 32 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Merewether
32 linked trials · page 1 of 1A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 · 2026-05-21 · 1 site observation
RECRUITING
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightNCT07339423 · 2026-02-24 · 1 site observation
RECRUITING
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossNCT07503210 · 2026-04-21 · 1 site observation
ACTIVE_NOT_RECRUITING
Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642 · 2025-11-05 · 1 site observation
ACTIVE_NOT_RECRUITING
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 · 2024-11-05 · 1 site observation
COMPLETED
Phase 2 Trials of NA-931 to Study Subjects Who Are Obese With at Least One Weight-related Comorbid ConditionNCT06564753 · 2024-07-19 · 1 site observation
COMPLETED
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 · 2024-01-16 · 1 site observation
COMPLETED
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 · 2023-11-27 · 1 site observation
COMPLETED
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 · 2023-11-25 · 1 site observation
COMPLETED
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 · 2023-09-27 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 · 2023-07-11 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 · 2023-07-10 · 1 site observation
COMPLETED
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620 · 2023-06-05 · 1 site observation
COMPLETED
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 · 2023-05-30 · 1 site observation
COMPLETED
SER150 vs Placebo in Diabetic Kidney DiseaseNCT04881123 · 2021-08-18 · 1 site observation
COMPLETED
Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney DiseaseNCT04419467 · 2020-09-14 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesNCT04255433 · 2020-05-29 · 1 site observation
COMPLETED
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.NCT04153929 · 2020-04-30 · 1 site observation
COMPLETED
A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump TherapyNCT03830281 · 2019-02-14 · 1 site observation
COMPLETED
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskNCT03730662 · 2018-11-20 · 1 site observation
COMPLETED
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 1 site observation
COMPLETED
Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 DiabetesNCT03254368 · 2017-09-12 · 1 site observation
COMPLETED
Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 YearsNCT03179423 · 2017-06-14 · 1 site observation
COMPLETED
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.NCT01320345 · 2016-11-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes MellitusNCT02453711 · 2015-10-01 · 1 site observation
COMPLETED
A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy AloneNCT02531035 · 2015-09-01 · 1 site observation
COMPLETED
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)NCT02414958 · 2015-06-30 · 1 site observation
COMPLETED
Linagliptin as Add on to Basal Insulin in the ElderlyNCT02240680 · 2014-09-23 · 1 site observation
COMPLETED
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD TherapyNCT01676116 · 2012-08-29 · 1 site observation
COMPLETED
A Study in Participants With Type I Diabetes MellitusNCT01454284 · 2012-01-01 · 1 site observation
COMPLETED
A Study in Patients With Type 2 Diabetes MellitusNCT01435616 · 2011-11-01 · 1 site observation
COMPLETED
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)NCT00310180 · 2006-04-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.